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ABSTRACT
Objective: To determine the effect of enteral glutamine in reducing the incidence of 
post burn infections in patients with severe burns.
Design: A double blind randomised clinical trial.
Setting: Burns unit and ward 4D of Kenyatta National Hospital, Kenya
Subjects: Sixty patients with severe burns who were randomised to two arms of 
treatment: (1) the glutamine group and (2) isonitrogenous arm acting as the control. 
Results: Patients’ demographic and baseline clinical characteristics were similar in 
both arms of treatment. For the entire four-week treatment period, the odds ratio of 
a positive blood culture was almost three-fold higher among patients in the control 
group compared to those in the Glutamine group (p = 0.04). There was also a higher 
incidence of positive swab cultures from the non glutamine group.
Conclusion: Enteral glutamine supplementation in severely burnt adult patients 
reduces blood infection by a factor of three. It also significantly reduces the incidence 
of burn wound infections.
INTRODUCTION
Incidence of burns-related infection has remained 
high despite different preventive modalities currently 
in use. These modalities include among others; topical 
antibacterial agents, early excision of eschar, and 
timely closure of burn wounds. All these methods 
have been demonstrated to significantly reduce the 
occurrence of invasive burn wound infection and its 
related mortality (1). However, severe thermal burns 
have an intrinsic systemic immunosuppressive effect 
and this could possibly explain the high incidence 
of burns related infection and mortality despite the 
aforementioned preventive modalities in use (2). In 
this regard, the concept of immunomodulation (in 
the prevention and management of burns related 
infections) has been introduced. This is exemplified 
by glutamine supplementation. 
 The incidence of burns-related infections is 
similar to that of trauma patients, with 50% being 
due to primary endogenous infections. The isolated 
pathogens are predominantly gram positive cocci 
(3). In a retrospective study done elsewhere, 71 % of 
hospitalised burn patients’ deaths were due to sepsis, 
septicaemia and complications of septicaemia (4). 
Incidence of burns-related infections and mortality 
rates among patients with moderate and severe burns 
in the local scene is 13.3% as reported by Nthumba & 
Oliech in a prospective analytical study of 2003 (5).
 Enteral glutamine has been demonstrated to be 
effective in decreasing infections in several clinical 
settings. For instance, in a prospective Randomized 
Controlled Trial (RCT) done by Castel, et al (6), 
infection rate in bone-marrow transplant patients 
who received glutamine supplemented nutrition 
was 12% as compared to 43% in non-supplemented 
group. 
 Similarly, infection rate was found to be three 
times lower in the glutamine group as opposed to 
the control group in patients with multiple trauma 
(7). Many of the clinical trials on enteral glutamine 
supplementation have focused on critically ill 
patients (with mixed diagnoses) such as trauma 
patients, oncological and haematological patients 
demonstrating positive effects on reduction of 
infection rates. However, there is limited published 
data focused on effect of enteral glutamine on 
infection rate in patients with severe burns. Results 
from recently published RCT on effects of enteral 
glutamine, show a trend of an overall reduction in 
incidence of bacteraemia, lower antibiotic usage and 
lower mortality rates in patients with severe burns 
(8-10). These results are particularly from developed 
countries and based on these studies majority of 
burn centres in Europe and United States of America 
routinely put their patients with severe burns on 
34 East african MEdical Journal January 2014 
glutamine-rich diet. In our local setting, the supply 
of glutamine is erratic and is only given to critically 
ill patients but not to severely burned patients. There 
was therefore a need for a local study to illustrate the 
efficacy of enteral glutamine in reduction of infectious, 
morbidity and mortality in patients with severe burns 
to justify routine supplementation of the same to this 
subset of patient population.  
MATERIALS AND METHODS
Study design and setting: Double blinded randomised 
clinical trial over a period of six months from 
September 2010 to February 2011 and carried out 
in the burns unit and plastic surgery ward 4D of 
Kenyatta National Hospital (KNH).
Study population: All patients with severe burns 
admitted in the burns unit and ward 4D.
Data collection and handling: All patients who satisfied 
the inclusion criteria and consented to the study were 
randomised into either the glutamine or the control 
group. The principal investigator collected the data 
using a predesigned questionnaire. Data were coded 
and entered into Microsoft excel spreadsheet and 
analysed using STATA version 9.2.
Ethical considerations: Necessary approvals were 
obtained from the Kenyatta National Hospital/
University of Nairobi Ethics and Research Committee 
(KNH/UoN-ERC). All the information gathered was 
kept confidential and was utilised for the purposes 
of this study only. 
RESULTS
A total of 240 wound surface cultures and 240 blood 
cultures were performed in the entire treatment 
period. All the sixty patients were included in the 
intention-to-treat analysis. The ages of the patients 
ranged from 17 to 74 years with a mean of 29.5 years 
(SD 10.7).
 Various micro-organisms were isolated from the 
pus swab cultures with the frequency of isolation 




Frequency of microbes isolated in pus swabs per treatment group




Odds Ratio  
(95% CI)
P
S Aureus 51/120(42.5%) 61/120(50.8%) 1.4(0.8-2.3)        0.2
Enterococcus 0/120(0) 2/120(1.7%) -        0.16
MRSA 8/120(6.7%) 2/120(1.6%) 0.23(0.05-1.2)        0.05
Pseudomonas spp 3/120(2.5%) 10/120(8.3%) 4.5(1.0-20)        0.03
Klebsiella spp 1/120(0.8%) 4/120(3.3%) 0.2(0.03-2.2)        0.17
Acinetobacter spp 5/120(4.1%) 7/120(5.8%) 1.4(0.4-4.6)        0.55
Proteus spp 2/120(1.6 %) 14/120(11.7%) 7.8(1.7-36.3)        0.002
The most common organism in both arms of treatment 
was Staphylococcus aureus; 42.5% and 50.8% in 
glutamine and fresubin respectively. Other common 
pathogens isolated in patients receiving glutamine-
free diet were proteus spp (11.7%) and pseudomonas 
spp (8.3%).
 Staphylococcus aureus remained the predominant 
organism isolated in both arms of treatment in the 
entire period of treatment. Gram negative bacteria 
such as pseudomonas spp started colonising the burn 
wound from day four onwards and its incidence rose 
sharply in the glutamine-free group in the last two 
weeks of treatment.
Overall, glutamine supplementation had a strong 
association with the reduction of the incidence of 
burn wound infection. Table  2 (p = 0.014).
 There were no significant differences in the 
incidence of positive swabs during week one or 
week two in the two groups (Table 2). During the 
third and fourth weeks the odds of positive culture 
were significantly higher in the fresubin group, with 
OR = 4.0 (1.2-12.8) and OR = 3.3 (0.9-11.7), respectively. 
The effect of glutamine on the incidence of infection 
reached a significant level in week three and four 
with p-value less than 0.05.
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Table 2
Positive swab cultures per week per treatment group
All patients (n = 60)
Glutamine  
(n = 120 swab cultures)
Fresubin   
(n = 120 swab cultures)




Total (week 1-week 4) 56/120(46.6%) 75/120(62.5%) 1.9(1.1-3.2) 0.014
Week 1 21/120(17.5%) 19/120(15.8%) 0.7(0.2-2.2) 0.58
Week 2 21/120(17.5%) 25/120(20.8%) 2.1 (0.6-7.6) 0.23
Week 3 9/120(7.5%) 19/120(15.8%) 4.0(1.2-12.8) 0.01
Week 4 5/120(4.1%) 12/120(10%) 3.3(0.9-11.7) 0.04
Out of the 240 blood cultures conducted among the 
60 patients over four weeks, a total of 54 bacterial 
pathogens were grown from 35 (58.3%) patients. 
The most common pathogen grown from blood 
cultures was staphylococcus aureus: 15.8% and 9.1% in 
the control and glutamine groups respectively. The 
least isolated microbe was proteus: 1.6% and 0% in 
the control and the glutamine group respectively. 
In respect to the other gram negative bacteria, it is 
evident from the Table 3 below that glutamine has a 
strong correlation with reduction in the incidence of 
infection caused by of klebsiela spp and pseudomonas 
spp at a p-value of 0.02 and 0.04 respectively. 
 
Table 3
Frequency of microbes isolated in blood culture per treatment group




Odds ratio  
(95% CI)
P
S Aureus 11/120(9.1%) 19/120(15.8%) 1.9(0.8-4.1) 0.12
Proteus spp 0/30(0) 2/120(1.6 %) - 0.15
Enterococcus 3/120(2.5%) 8/120(6.7%) 2.8(0.7-10.8) 0.12
MRSA 3/120(2.5%) 2/120(1.6%) 0.6(0.1-4.0) 0.65
Klebsiella spp 0/120 5/120(4.1%) - 0.02
Pseudomonas spp 5/120(4.1%) 12/120(10%) 3.3(0.9-11.7) 0.04
In the first two weeks the rate of positive blood cultures remained the same in both treatment arms, with 
the glutamine free arm showing a significantly sharp increase from the third week. Table 4.
 
Table 4
Frequeny of positive blood culture per treatment group at different time points





Odds ratio  
(95% CI)
P
Positive blood culture 
Total (week 1-week 4) 13/120(10.8%) 30/120(25%) 2.7 (1.3-5.6) 0.004
Weekly positive blood 
cultures
Week 1 1/120(0.83) 1/120(0.83%) 1.0(0.06-17.2) 0.99
Week 2 8/120(6.7%) 7/120(5.8%) 0.8(0.25-2.7) 0.76
Week 3 2/120(1.6 %) 14/120(11.7%) 7.8(1.7-36.3) 0.002
Week 4 3/120(2.5%) 10/120(8.3%) 4.5(1.0-20) 0.03
36 East african MEdical Journal January 2014 
DISCUSSION
 Infection in patients with severe burns remains a 
major challenge and a major cause of morbidity and 
mortality especially in the developing countries (1). 
 Gram negative bacteria such as pseudomonas and 
proteus were isolated from the swab cultures from 
day four onward with the incidence being higher 
in the last two weeks in the non glutamine group. 
This compares closely with a study done in Syria by 
Dayoub in 19954.
 Glutamine does not seem to have a significant 
impact on the incidence of bacteraemia in the first 
two weeks. These results are similar to findings by 
Garrel in 2003 in a randomised controlled trial (9). 
The study also compares closely with the results of 
a study done in India in 2009 (11).  This study also 
shows that glutamine reduced the incidence of gram 
negative bacteria such as Pseudomonas spp by 3.3 to 
4.5 times. Overall, there was a lower incidence of 
infection in the glutamine group as opposed to the 
control group as evidenced by swab cultures and 
blood cultures.
 It is recommended that criteria for the use of 
glutamine in patients with severe burns be developed 
as it is evident that it is beneficial in reducing the 
incidence of infection.
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